JP6949468B2 - 腫瘍抗原をコードする麻疹ウイルス - Google Patents
腫瘍抗原をコードする麻疹ウイルス Download PDFInfo
- Publication number
- JP6949468B2 JP6949468B2 JP2016203835A JP2016203835A JP6949468B2 JP 6949468 B2 JP6949468 B2 JP 6949468B2 JP 2016203835 A JP2016203835 A JP 2016203835A JP 2016203835 A JP2016203835 A JP 2016203835A JP 6949468 B2 JP6949468 B2 JP 6949468B2
- Authority
- JP
- Japan
- Prior art keywords
- recombinant virus
- paramyxoviridae family
- cancer
- virus
- paramyxoviridae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 233
- 239000000427 antigen Substances 0.000 title claims description 171
- 108091007433 antigens Proteins 0.000 title claims description 171
- 102000036639 antigens Human genes 0.000 title claims description 171
- 241000712079 Measles morbillivirus Species 0.000 title claims description 47
- 241000700605 Viruses Species 0.000 claims description 192
- 102000040430 polynucleotide Human genes 0.000 claims description 165
- 108091033319 polynucleotide Proteins 0.000 claims description 165
- 239000002157 polynucleotide Substances 0.000 claims description 165
- 210000004027 cell Anatomy 0.000 claims description 141
- 241000711504 Paramyxoviridae Species 0.000 claims description 120
- 201000011510 cancer Diseases 0.000 claims description 87
- 239000012634 fragment Substances 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 69
- 230000028993 immune response Effects 0.000 claims description 50
- 210000002865 immune cell Anatomy 0.000 claims description 43
- 150000007523 nucleic acids Chemical group 0.000 claims description 26
- 239000012190 activator Substances 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000000259 anti-tumor effect Effects 0.000 claims description 16
- 230000000890 antigenic effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- VJNCICVKUHKIIV-LURJTMIESA-N L-dopachrome Chemical compound O=C1C(=O)C=C2N[C@H](C(=O)O)CC2=C1 VJNCICVKUHKIIV-LURJTMIESA-N 0.000 claims description 4
- 241000712045 Morbillivirus Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 100
- 102000004196 processed proteins & peptides Human genes 0.000 description 87
- 229920001184 polypeptide Polymers 0.000 description 83
- 241000701806 Human papillomavirus Species 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 24
- 230000003612 virological effect Effects 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 230000027455 binding Effects 0.000 description 19
- 230000004927 fusion Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 238000012737 microarray-based gene expression Methods 0.000 description 12
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 8
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 7
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 7
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 102100032187 Androgen receptor Human genes 0.000 description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 6
- 102100023328 G-protein coupled estrogen receptor 1 Human genes 0.000 description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 6
- 102000043131 MHC class II family Human genes 0.000 description 6
- 108091054438 MHC class II family Proteins 0.000 description 6
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 108010080146 androgen receptors Proteins 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 241001493065 dsRNA viruses Species 0.000 description 6
- 108091008588 membrane estrogen receptors Proteins 0.000 description 6
- 102000003998 progesterone receptors Human genes 0.000 description 6
- 108090000468 progesterone receptors Proteins 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 5
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 244000309459 oncolytic virus Species 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 4
- 108700019961 Neoplasm Genes Proteins 0.000 description 4
- 102000048850 Neoplasm Genes Human genes 0.000 description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002601 intratumoral effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 3
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108010010995 MART-1 Antigen Proteins 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 102000004874 Synaptophysin Human genes 0.000 description 3
- 108090001076 Synaptophysin Proteins 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 101150062031 L gene Proteins 0.000 description 2
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 2
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 208000010505 Nose Neoplasms Diseases 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 101150084044 P gene Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 201000003970 colon lymphoma Diseases 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 208000037830 nasal cancer Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000037968 sinus cancer Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000004500 stellate cell Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 229940124862 Measles virus vaccine Drugs 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229940123751 PD-L1 antagonist Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 102000046158 human CTAG1B Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000037449 immunogenic cell death Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 208000022982 optic pathway glioma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0015—Combination vaccines based on measles-mumps-rubella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18471—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/04—Uses of viruses as vector in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
(a) (i) 本発明のパラミクソウイルス科の組換えウイルス、
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは以下に明記される実施形態に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルスおよび/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する、宿主細胞;好ましくは以下に明記される実施形態に記載の宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ;ならびに
(b) 少なくとも1つの薬理学上許容される添加剤。
a) がん細胞および免疫細胞を含む前記サンプルを
(i) 本発明のパラミクソウイルス科の組換えウイルス、
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは以下に明記される実施形態に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは以下に明記される実施形態に記載の宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ
と接触させること;ならびにそれによって
b) 前記サンプルに含まれる、抗腫瘍活性を有する免疫細胞を活性化すること。
1. a) 前記被験体を
2. (i) 本発明のパラミクソウイルス科の組換えウイルス、
3. (ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは本明細書に明記される実施形態に記載のポリヌクレオチド;
4. (iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは本明細書に明記される実施形態に記載の宿主細胞;または
5. (iv) (i)〜(iii)の任意の組み合わせ
と接触させること;ならびにそれによって
b)がんを患う被験体においてがんを治療すること。
1. (i) 本発明のパラミクソウイルス科の組換えウイルス、
2. (ii)(i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは下記に明記される実施形態に記載のポリヌクレオチド;
3. (iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは下記に明記される実施形態に記載の宿主細胞;または
4. (iv) (i)〜(iii)の任意の組み合わせ。
1. (i) 請求項1〜20のいずれか1つに記載のパラミクソウイルス科の組換えウイルス、
2. (ii)(i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは下記に明記される実施形態に記載のポリヌクレオチド;
3. (iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは下記に明記される実施形態に記載の宿主細胞;または
4. (iv) (i)〜(iii)の任意の組み合わせ。
a) 前記被験体のがんサンプルにおいて、がん細胞によって発現される少なくとも1つの腫瘍抗原を検出すること;ならびに
b) ステップa)に基づいて、腫瘍抗原またはその断片もしくはそのバリアントをコードする発現可能なポリヌクレオチドを含有する、組換えウイルス、ポリヌクレオチド、および/または宿主細胞を検出すること
を含む。
請求/実施形態
1. (i)〜(iii) のうち少なくとも1つ、すなわち、(i)腫瘍抗原、(ii)腫瘍抗原の断片、および(iii) (i)または(ii)のバリアントのうち少なくとも1つをコードする、発現可能なポリヌクレオチドを含有する、パラミクソウイルス科の組換えウイルス。
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態21または22に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態23または24に記載の宿主細胞;または
(iv) (i)〜(iii)のいずれかの組み合わせ;ならびに
(b) 少なくとも1つの薬理学上許容される添加剤
を含む薬剤。
(a) (i) 実施形態1〜20のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態21または22に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態23または24に記載の宿主細胞;または
(iv) (i)〜(iii)のいずれかの組み合わせ;
と、がん細胞および免疫細胞を含む前記サンプルを接触させること;ならびに、それによって
(b) 前記サンプル中に含まれる抗腫瘍活性を有する免疫細胞を活性化すること;
を含む、前記方法。
(a) (i) 実施形態1〜20のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態21または22に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態23または24に記載の宿主細胞;または
(iv) (i)〜(iii)のいずれかの組み合わせ;
と、前記被験体を接触させること;ならびに、それによって
(b) がんに罹っている被験体においてがんを治療すること;
を含む、前記方法。
(i) 実施形態1〜20のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態21または22に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態23または24に記載の宿主細胞;または
(iv) (i)〜(iii)のいずれかの組み合わせ;
の使用。
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態21または22に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態23または24に記載の宿主細胞;または
(iv) (i)〜(iii)のいずれかの組み合わせ;
を容器内に収納して含む、キット。
a) 前記被験体のがんサンプルにおいて、がん細胞により発現される少なくとも1つの腫瘍抗原を検出すること;ならびに
b) ステップa)の測定に基づいて、腫瘍抗原、またはその断片もしくはそのバリアントをコードする発現可能なポリヌクレオチドを含有する、組換えウイルス、ポリヌクレオチド、および/または宿主細胞を選択すること
を含む、前記方法。
(i)の組換えウイルスが、実施形態1〜20のいずれか1つに記載の組換えウイルスであり;
(ii)のポリヌクレオチドが、実施形態21または22に記載のポリヌクレオチドである;および/または
(iii)の宿主細胞が、実施形態23または24に記載の宿主細胞である、
前記方法。
本開示は以下の実施形態を包含する。
[1] (i)腫瘍抗原、(ii)腫瘍抗原の断片、および(iii) (i)または(ii)のバリアント、のうち少なくとも1つをコードする、発現可能なポリヌクレオチドを含有する、パラミクソウイルス科の組換えウイルス。
[2] 前記腫瘍抗原が、L-ドパクロムトートメラーゼ(TRP2)、メラニン細胞タンパク質PMEL(gp100)、HPV E6/7、MAGE 1、MAGE 3、NY-ESO、アンドロゲン受容体(AR)、BCL-1、カルプロテクチン、がん胎児性抗原(CEA)、EGFR、上皮細胞接着分子(Ep-CAM)、上皮性シアロムチン、膜エストロゲン受容体(mER)、FAP HER2/neu、ヒト高分子量メラノーマ関連抗原(HMW-MAA)、IL-6、MOC-1、MOC-21、MOC-52、melan-A/MART-1、メラノーマ関連抗原、ムチン、OKT9、プロゲステロン受容体(PGR)、前立腺特異抗原(PSA)、前立腺幹細胞抗原(PSCA)、前立腺特異的膜抗原(PSMA)、シナプトフィジン、VEGFR、CD19、CD20、CD22、CD30、およびCD33からなる一群から選択される、実施形態1に記載のパラミクソウイルス科の組換えウイルス。 より好ましくは、腫瘍抗原が、HPV E6/7、MAGE 1、MAGE 3、NY-ESO、TRP2もしくはgp100であり、さらに好ましくはTRP2である。
[3] 前記断片が前記腫瘍抗原の少なくとも1つの抗原性エピトープを含有する、実施形態1または2に記載のパラミクソウイルス科の組換えウイルス。
[4] 前記腫瘍抗原、その断片もしくはそのバリアントが、(i) ヒトパピローマウイルス(HPV)E6ポリペプチド、好ましくはハイリスクHPVのE6ポリペプチド、たとえばHPV16 E6、またはその断片および/またはそのバリアント;(ii) HPV E7ポリペプチド、好ましくはハイリスクHPVのE7ポリペプチド、たとえばHPV16 E7、またはその断片および/またはそのバリアント;(iii) TRP2、好ましくはヒトTRP2、またはその断片および/またはそのバリアント;(iv) がん/精巣抗原1B(CTAG1B)、好ましくはヒトCTAG1B、またはその断片および/またはそのバリアント;ならびに(v) (i)〜(iv)のいずれかの任意の組み合わせ、のうち少なくとも1つを含み、好ましくはそれらからなる、実施形態1〜3のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
[5] 前記組換えウイルスが、組換えモルビリウイルス属、好ましくは組換え麻疹ウイルス(MV)である、実施形態1〜4のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
[6] さらなる免疫応答アクチベーターをコードする少なくとも1つの発現可能なポリヌクレオチドをさらに含有する、実施形態1〜5のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
[7] 前記の少なくとも1つの発現可能なポリヌクレオチドが、パラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドに含まれるものである、実施形態1〜6のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
[8] 前記のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドが、配列番号3〜5のいずれか1つの核酸配列を含み、好ましくはその核酸配列からなる、実施形態1〜7のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
[9] 実施形態1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド。
[10] 実施形態1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス、および/または実施形態9に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞。
[11] がん細胞および免疫細胞を含むサンプルにおいて、抗腫瘍活性を有する免疫細胞を活性化するための方法であって、
a) (i) 実施形態1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態9に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態10に記載の宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ
と、がん細胞および免疫細胞を含む前記サンプルとを接触させること;ならびに、それによって
b) 前記サンプル中に含まれる抗腫瘍活性を有する免疫細胞を活性化すること;
を含む、前記方法。
[12] 実施形態11に記載の方法によって得られた、または得ることができる、抗腫瘍活性を有する活性化された免疫細胞の標品。
[13] 薬剤を製造するための、好ましくは、不適切な細胞増殖を治療するための薬剤を製造するための、
(i) 実施形態1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態9に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態10に記載の宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ
の使用。
[14] 前記の不適切な細胞増殖ががんである、実施形態13に記載の使用。
[15] (i) 実施形態1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) (i)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド、好ましくは、実施形態9に記載のポリヌクレオチド;
(iii) (i)に記載のパラミクソウイルス科の組換えウイルス、および/または(ii)に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞;好ましくは実施形態10に記載の宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ
を容器内に収納して含む、キット。
Claims (16)
- (i)腫瘍抗原L-ドパクロムトートメラーゼ(TRP2)、(ii)TRP2の少なくとも1つの抗原性エピトープを含有する腫瘍抗原TRP2の断片、および(iii) (i)または(ii)のバリアント、のうち少なくとも1つをコードする、発現可能なポリヌクレオチドを含有する、複製能を有するパラミクソウイルス科の組換えウイルスであって、該バリアントは配列番号2に示されるTRP2のアミノ酸配列と90%以上の配列同一性を有する、前記ウイルス。
- 前記TRP2の抗原性エピトープが一連の少なくとも7個から15個のアミノ酸を含む、請求項1に記載のパラミクソウイルス科の組換えウイルス。
- 前記腫瘍抗原TRP2が、ヒトTRP2である、請求項1又は2に記載のパラミクソウイルス科の組換えウイルス。
- 前記組換えウイルスが、組換えモルビリウイルス属のウイルスである、請求項1〜3のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
- 前記組換えモルビリウイルス属のウイルスが、組換え麻疹ウイルス(MV)である、請求項4に記載のパラミクソウイルス科の組換えウイルス。
- さらなる免疫応答アクチベーターをコードする少なくとも1つの発現可能なポリヌクレオチドをさらに含有する、請求項1〜5のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
- 前記の少なくとも1つの発現可能なポリヌクレオチドが、パラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドに含まれるものである、請求項1〜6のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
- 前記のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドが、配列番号3〜5のいずれか1つの核酸配列を含む、請求項1〜7のいずれか1つに記載のパラミクソウイルス科の組換えウイルス。
- 請求項1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド。
- 請求項1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス、および/または請求項9に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチドを含有する宿主細胞。
- がん細胞および免疫細胞を含むサンプルにおいて、抗腫瘍活性を有する免疫細胞を活性化するための方法であって、
a) (i) 請求項1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) 請求項9に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド;
(iii) 請求項10に記載のパラミクソウイルス科の組換えウイルスを含有する宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ
と、がん細胞および免疫細胞を含む前記サンプルとを接触させること;ならびに、それによって
b) 前記サンプル中に含まれる抗腫瘍活性を有する免疫細胞を活性化すること;
を含む、前記方法。 - 請求項11に記載の方法によって得られた、または得ることができる、抗腫瘍活性を有する活性化された免疫細胞の標品。
- 薬剤を製造するための、
(i) 請求項1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) 請求項9に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド;
(iii) 請求項10に記載のパラミクソウイルス科の組換えウイルスを含有する宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ
の使用。 - 薬剤が、不適切な細胞増殖を治療するための薬剤である、請求項13に記載の使用。
- 前記の不適切な細胞増殖ががんである、請求項13又は14に記載の使用。
- (i) 請求項1〜8のいずれか1つに記載のパラミクソウイルス科の組換えウイルス;
(ii) 請求項9に記載のパラミクソウイルス科の組換えウイルスをコードするポリヌクレオチド;
(iii) 請求項10に記載のパラミクソウイルス科の組換えウイルスを含有する宿主細胞;または
(iv) (i)〜(iii)の任意の組み合わせ
を容器内に収納して含む、キット。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016203835A JP6949468B2 (ja) | 2016-10-17 | 2016-10-17 | 腫瘍抗原をコードする麻疹ウイルス |
AU2017202406A AU2017202406B2 (en) | 2016-10-17 | 2017-04-11 | Measles Virus Encoding a Tumor Antigen |
CA2964462A CA2964462A1 (en) | 2016-10-17 | 2017-04-13 | Measles virus encoding a tumor antigen |
US15/784,895 US11369669B2 (en) | 2016-10-17 | 2017-10-16 | Measles virus encoding a tumor antigen |
JP2021154467A JP2022008506A (ja) | 2016-10-17 | 2021-09-22 | 腫瘍抗原をコードする麻疹ウイルス |
US17/747,557 US20230069933A1 (en) | 2016-10-17 | 2022-05-18 | Measles virus encoding a tumor antigen |
JP2023159200A JP2023179549A (ja) | 2016-10-17 | 2023-09-22 | 腫瘍抗原をコードする麻疹ウイルス |
AU2023282166A AU2023282166A1 (en) | 2016-10-17 | 2023-12-11 | Measles Virus Encoding a Tumor Antigen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016203835A JP6949468B2 (ja) | 2016-10-17 | 2016-10-17 | 腫瘍抗原をコードする麻疹ウイルス |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021154467A Division JP2022008506A (ja) | 2016-10-17 | 2021-09-22 | 腫瘍抗原をコードする麻疹ウイルス |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018078802A JP2018078802A (ja) | 2018-05-24 |
JP6949468B2 true JP6949468B2 (ja) | 2021-10-13 |
Family
ID=61968919
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016203835A Active JP6949468B2 (ja) | 2016-10-17 | 2016-10-17 | 腫瘍抗原をコードする麻疹ウイルス |
JP2021154467A Pending JP2022008506A (ja) | 2016-10-17 | 2021-09-22 | 腫瘍抗原をコードする麻疹ウイルス |
JP2023159200A Pending JP2023179549A (ja) | 2016-10-17 | 2023-09-22 | 腫瘍抗原をコードする麻疹ウイルス |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021154467A Pending JP2022008506A (ja) | 2016-10-17 | 2021-09-22 | 腫瘍抗原をコードする麻疹ウイルス |
JP2023159200A Pending JP2023179549A (ja) | 2016-10-17 | 2023-09-22 | 腫瘍抗原をコードする麻疹ウイルス |
Country Status (4)
Country | Link |
---|---|
US (2) | US11369669B2 (ja) |
JP (3) | JP6949468B2 (ja) |
AU (2) | AU2017202406B2 (ja) |
CA (1) | CA2964462A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111748017A (zh) * | 2019-03-26 | 2020-10-09 | 上海瑞可新生物科技有限公司 | 一种抗原多肽及其表达载体、组合药物、试剂盒和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
US6764685B1 (en) * | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
JP4791651B2 (ja) * | 2000-05-18 | 2011-10-12 | 株式会社ディナベック研究所 | 外来遺伝子導入用パラミクソウイルスベクター |
ES2330309T3 (es) * | 2002-06-20 | 2009-12-09 | Institut Pasteur | Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas. |
CA2614322A1 (en) | 2005-07-14 | 2007-01-25 | Mayo Foundation For Medical Education And Research | Paramyxoviridae virus preparations |
EP2669381A1 (en) * | 2012-05-30 | 2013-12-04 | AmVac AG | Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein |
ES2741147T3 (es) * | 2013-02-21 | 2020-02-10 | Turnstone Lp | Composición de vacuna |
US10933106B2 (en) | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
-
2016
- 2016-10-17 JP JP2016203835A patent/JP6949468B2/ja active Active
-
2017
- 2017-04-11 AU AU2017202406A patent/AU2017202406B2/en active Active
- 2017-04-13 CA CA2964462A patent/CA2964462A1/en active Pending
- 2017-10-16 US US15/784,895 patent/US11369669B2/en active Active
-
2021
- 2021-09-22 JP JP2021154467A patent/JP2022008506A/ja active Pending
-
2022
- 2022-05-18 US US17/747,557 patent/US20230069933A1/en active Pending
-
2023
- 2023-09-22 JP JP2023159200A patent/JP2023179549A/ja active Pending
- 2023-12-11 AU AU2023282166A patent/AU2023282166A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023179549A (ja) | 2023-12-19 |
US20180110848A1 (en) | 2018-04-26 |
AU2023282166A1 (en) | 2024-01-04 |
AU2017202406A1 (en) | 2018-05-10 |
US20230069933A1 (en) | 2023-03-09 |
CA2964462A1 (en) | 2018-04-17 |
JP2018078802A (ja) | 2018-05-24 |
AU2017202406B2 (en) | 2023-12-21 |
US11369669B2 (en) | 2022-06-28 |
JP2022008506A (ja) | 2022-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7280827B2 (ja) | Axlまたはror2に対するキメラ抗原受容体およびその使用方法 | |
JP2021176880A (ja) | Il−15ベース分子及びその使用方法 | |
BR112020014121A2 (pt) | anticorpos anti-pd-1 e métodos de tratamento | |
CN105452288A (zh) | 抗人乳头瘤病毒16 e6 t细胞受体 | |
AU2017213661A1 (en) | Administration of engineered T cells for treatment of cancers in the central nervous system | |
JP2021510081A (ja) | 抗体修飾キメラ抗原受容体修飾t細胞及びその使用 | |
US10344067B2 (en) | RNA viruses expressing IL-12 for immunovirotherapy | |
JP2022520285A (ja) | 低酸素応答性キメラ抗原受容体 | |
US20190099461A1 (en) | Rna viruses for immunovirotherapy | |
JP2022527267A (ja) | T細胞受容体及びその使用方法 | |
US20210353696A1 (en) | Herpesvirus with Modified Glycoprotein B | |
CN112601761A (zh) | 结合ox40的多肽及其用途 | |
JP2023179549A (ja) | 腫瘍抗原をコードする麻疹ウイルス | |
JP2022519377A (ja) | がんのバイオマーカーとしてのil-4r | |
CN117222421A (zh) | T细胞调节多肽和其使用方法 | |
JP2024526835A (ja) | Cd8結合ポリペプチド及びその使用 | |
JP2020535832A (ja) | マウス定常領域を伴うtcrを発現する細胞を選択的に増幅するための方法 | |
JP2023549116A (ja) | 選択性が増大した多標的二重特異性抗原結合分子 | |
JP2022523552A (ja) | T細胞受容体及びその使用方法 | |
JP2022524993A (ja) | T細胞受容体及びその使用方法 | |
JP2022524994A (ja) | T細胞受容体及びその使用方法 | |
CA2921864C (en) | Rna viruses expressing il-12 for immunovirotherapy | |
JP2022523553A (ja) | T細胞受容体及びその使用方法 | |
JP2022523971A (ja) | T細胞受容体及びその使用方法 | |
JP2022523554A (ja) | T細胞受容体及びその使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20161116 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170531 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190930 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210601 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210824 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210922 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6949468 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |